In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

QAD Helps Manufacturers Form Strategies to Accommodate the New U.S. Medical Device Excise Tax

New White Paper Now Available from QAD

SANTA BARBARA, Calif. — June 05, 2013 — QAD Inc. (NASDAQ:QADA) (NASDAQ:QADB), a leading provider of enterprise software and services, is providing guidance on how QAD Enterprise Applications can help companies comply with the U.S. medical device excise tax with the release of a complimentary new white paper. The new white paper from QAD helps medical device manufacturers understand the impact of the excise tax and form strategies to accommodate implementation and compliance with regulatory demands.

The new excise tax applies to manufacturers, producers and importers of taxable medical devices. Hospitals and other health care providers may, in some situations, also be liable for the excise tax. QAD helps customers decide on a clear plan of action.

“The U.S. medical device excise tax impacts a number of company functions – from sales and pricing strategy to distribution,” said Dave Medina, vice president of Life Sciences at QAD. “We work closely with our customers to help them make effective decisions about the right options presented in the excise tax. And we support the rapid implementation that ensures our customers’ information systems continue to meet ever changing regulations today and in the future.”

The Effective Enterprise for Life Sciences

QAD Enterprise Applications enables life sciences companies to meet the critical quality requirements for manufacturing innovative, safe and effective healthcare products in compliance with global regulatory standards. Intuitive, easy-to-use industry best practices are built into QAD Enterprise Applications for flexible deployment onsite or on demand to support global life sciences companies, all supporting current good manufacturing practices (cGMPs).

“QAD knows manufacturing companies in life sciences want to deliver innovative healthcare products that are safe and effective,” added Medina. “QAD is committed to helping medical device manufacturers meet the vision of an Effective Enterprise in life sciences by becoming patient-focused, compliant and innovative – today and in the future.”

For more information about QAD Enterprise Applications, please visit: www.qad.com.

About QAD

QAD is a leading provider of enterprise applications for global manufacturing companies specializing in automotive, consumer products, electronics, food and beverage, industrial and life sciences products. QAD ERP solutions provide critical functionality for managing manufacturing resources and operations within and beyond the enterprise, enabling global manufacturers to collaborate with their customers, suppliers and partners to make and deliver the right product, at the right cost and at the right time. For more information about QAD, telephone +1 805-566-6000, or visit the QAD web site at www.qad.com.

“QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.

For additional information, contact:

Ashley DeVan
Sr. Director of Marketing Communications
QAD Inc.
+1 805 566 6126
ashley.devan@qad.com
Heidi Wieland
Media Relations
QAD Inc.
+1 805 565 2452
Heidi.wieland@qad.com

Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expects”, “believes”, “anticipates”, “could”, “will likely result”, “estimates”, “intends”, “may”, “projects”, “should”, and variations of these words and similar expressions are intended to identify these forward looking statements. Forward-looking statements are based on the company’s current expectations and assumptions regarding its business, the economy and future conditions. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to, evolving demand for the company's software products and products that operate with the company's products; the company's ability to sustain license and service demand; the company's ability to leverage changes in technology; the company's ability to sustain customer renewal rates at current levels; the publication of opinions by industry and financial analysts about the company, its products and technology; the reliability of estimates of transaction and integration costs and benefits; the entry of new competitors or new offerings by existing competitors and the associated announcement of new products and technological advances by them; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales as a result of lengthy sales cycles; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. In addition, revenue and earnings in the enterprise resource planning (ERP) software industry are subject to fluctuations. Software license revenue, in particular, is subject to variability with a significant proportion of revenue earned in the last month of each quarter. Given the high margins associated with license revenue, modest fluctuations can have a substantial impact on net income. Investors should not use any one quarter's results as a benchmark for future performance. For a more detailed description of the risk factors associated with the company and the industries in which it operates, please refer to the company's Annual Report on Form 10-K for fiscal 2013 ended January 31, 2013, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission.